Q1 2026 produced four hardware-driven digital health mega-rounds in one quarter. Whoop at $10.1B. Neuralink at $9.7B. BrainCo at $1.3B unicorn birth. eMed at $2B. Either hardware is back or this is the top.
Context: Peloton went from $171 to under $4. Lululemon wrote off Mirror entirely. Fitbit got swallowed by Google. The consensus by late 2024 was that consumer health hardware without a regulatory moat was getting bundled into irrelevance by Apple Watch.
What changed: Whoop and Oura are not hardware companies in any traditional sense. The device is the acquisition cost for a subscription and a compounding data relationship. Oura has clinical partnerships with the Cleveland Clinic and the Department of Defense. These are data platforms.
The underappreciated piece: BrainCo and Stairmed, both backed by major Chinese capital, are running BCI development programs that do not need FDA timelines. Stairmed has reportedly completed its own first human implant. The Chinese BCI cohort is closer to Neuralink than most Western investors know.
Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more.
